Skip to main content
profile image
Selected Works of Philip Mease, MD
Presentation
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. Australian Rheumatology Association (ARA) ASM, Auckland NZ, May 2017.
Australian Rheumatology Association (ARA) ASM (2017)
  • S Hall
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Link
Disciplines
Publication Date
May, 2017
Citation Information
S Hall, Philip Mease and et.al.. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. Australian Rheumatology Association (ARA) ASM, Auckland NZ, May 2017." Australian Rheumatology Association (ARA) ASM (2017)
Available at: http://works.bepress.com/philip-mease/272/